



臺中榮民總醫院  
Taichung Veterans General Hospital


# 臨床試驗中Risk of Bias的評估 與統合分析技術應用

臺中榮民總醫院 醫學研究部 基礎醫學科  
高級助理研究員 陳韻仔博士




# 百年前的「臨床試驗」

- 詹姆斯·林德 ( James Lind · 1716年 - 1794年 6月13日 )
  - 英國皇家海軍外科醫生 ( 1739年 - 1748年 ) ，英格蘭衛生學的創始人
  - 發起利用柑桔類水果和新鮮蔬菜治療和預防壞血病
  - A treatise of the scurvy 壞血病論



# 百年前的「臨床試驗」

- 百年前的歐洲，長期在海上航行的水手經常遭受壞血病的折磨，患者常常牙齦出血，甚至皮膚淤血和滲血，最後痛苦地死去，人們一直查不出病因。奇怪的是，只要船隻靠岸，這種疾病很快就不治而癒了。
- **問題：**水手們為什麼會得壞血病呢？
- 書中提到他在1747年在船上做了一個**臨床試驗：**
  - 出現壞血病的船員，大家都吃完全相同的食物
  - 唯一不同的是有些病人每天吃兩個橘子和一個檸檬，其他的人喝蘋果酒、稀硫酸、醋、海水。
- **實驗的結論：**吃柑橘水果的**兩人**好轉，其它人病情依然。



# 偏差？

---

- 從現代的觀點看，林德的臨床試驗不夠嚴謹：
  - 病人的分派 Allocation
  - 每一組的病人數 Sample size
  - 臨床指標 Clinical indication / Outcome
  - 統計分析 Statistical analysis

# “Bias” v.s. “Risk of Bias”


抽樣所造成測量值與真實值之間的差異，統計可處理：  
通過多次測量或增加樣本數，獲得的均值儘量逼近

- Error – Systematic error v.s. **Random error** →
- Bias – Systematic error
  - Deviation of study result from the truth，不能靠統計處理
  - 測量時即發生錯誤 (內因)：Information bias, recall bias, report bias
  - 外因：Confounding bias ~ Confounding factors
- Risk of Bias
  - In fact, we never know the truth
  - The results from a study might be unbiased despite methodological flaws
    - ✓ E.g., **poor randomization** or lost to follow up, but unbiased results

# 實證醫學的證據等級

- 文獻的證據等級與研究設計相關

證據金字塔 → 隨機對照試驗 (RCT) :  
Level 1 (Gold Standard)



# 實證醫學的證據等級

- 文獻的證據等級與研究設計相關
- 證據的等級：良好研究設計可以減少偏差的程度→**隨機對照試驗 (RCT)**

表一 Oxford證據等級與建議等級<sup>6, 9</sup>

建議等級	證據等級	證據的型態
[A]	1a	同質性隨機對照試驗的系統性回顧
	1b	單獨的隨機對照試驗
	1c	如果沒有給藥的全部病人會死，給藥後會有一些病人存活；或是如果沒有給藥會有一些病人死亡，而給藥後就不會有病人死亡。
[B]	2a	同質性世代研究的系統性文獻回顧
	2b	單獨的世代研究
	2c	結果研究或生態研究
	3a	同質性個案研究的系統性文獻回顧
	3b	單獨的個案對照研究
[C]	4	個案發現報告或是品質較差的世代研究和個案對照研究
[D]	5	未經清楚且嚴謹的專家意見



# 為什麼要進行Meta-analysis?

統合多個臨床研究的樣本數和結果，證據力高  
花費研究經費和人力成本相對低






圖2 統合分析中呈現不同研究結果的明顯差異性

## 科學證據強度分級金字塔





# 統合分析的研究品質對分析結果的影響



# 使用RCT研究進行統合分析→確認研究品質

## Domain-based approach in Cochrane's "Risk of bias" (ROB) tool (for RCT)

- Sequence generation
- Allocation concealment
- Blinding of participants, personnel and outcome assessors
- Incomplete outcome data
- Selective outcome reporting
- Other sources of bias

由兩個人double check

# 使用RCT研究進行統合分析→確認研究品質

## Domain-based approach in Cochrane's "Risk of bias" (ROB) tool (for RCT)

Domain	Signalling question	Response
Bias arising from the randomization process	1.1 Was the allocation sequence random?	Y
	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?	Y
	1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?	Y
	<b>Risk of bias judgement</b>	<b>Some concerns</b>

# 使用RCT研究進行統合分析→確認研究品質

## Domain-based approach in Cochrane's "Risk of bias" (ROB) tool (for RCT)

Domain	Signalling question	Response
Bias due to deviations from intended interventions	2.1. Were participants aware of their assigned intervention during the trial?	N
	2.2. Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?	N
	2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?	NA
	2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?	NA
	2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?	NA
	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?	NA
	2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?	N
	<b>Risk of bias judgement</b>	<b>Low</b>

# 使用RCT研究進行統合分析→確認研究品質

## Domain-based approach in Cochrane's "Risk of bias" (ROB) tool (for RCT)

Domain	Signalling question	Response
Bias due to missing outcome data	3.1 Were data for this outcome available for all, or nearly all, participants randomized?	Y
	3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?	NA
	3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?	NA
	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	NA
	<b>Risk of bias judgement</b>	<b>Low</b>

# 使用RCT研究進行統合分析→確認研究品質

## Domain-based approach in Cochrane's "Risk of bias" (ROB) tool (for RCT)

Domain	Signalling question	Response
<b>Bias in measurement of the outcome</b>	4.1 Was the method of measuring the outcome inappropriate?	N
	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	N
	4.3 Were outcome assessors aware of the intervention received by study participants?	N
	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	NA
	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	NA
	<b>Risk of bias judgement</b>	

# 使用RCT研究進行統合分析→確認研究品質

## Domain-based approach in Cochrane's "Risk of bias" (ROB) tool (for RCT)

Domain	Signalling question	Response
Bias in selection of the reported result	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	Y
	5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	N
	5.3 ... multiple eligible analyses of the data?	N
	<b>Risk of bias judgement</b>	<b>Low</b>

# 使用RCT研究進行統合分析→確認研究品質


## ROB Summary

Studies with intention-to-treat	Unique ID	Study ID	Experimental	Comparator	Outcome	Weight	Randomization process	Deviations from intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported result	Overall		
	McKay C_19	McKay C_1997	Octreotide	Placebo	Organ failure	1	?	+	+	+	+	+	+	Low risk
	McKay CJ_1	McKay CJ_1997	Lexipafant	Placebo	Organ failure	1	?	+	+	+	+	+	+	Some concerns
	Sateesh J_20	Siriwardena AK	Antioxidants	Placebo	Organ failure	1	+	+	+	+	+	+	+	Low risk
	Siriwardena	Siriwardena AK	Antioxidants	Placebo	Organ failure	1	?	+	+	+	+	+	+	Some concerns
	Tozlu M_20	Tozlu M_2019	LMWH	Placebo	Organ failure	1	+	+	+	+	+	+	+	Low risk
	Vege SS_20	Vege SS_2015	Pentoxifylline	Placebo	Organ failure	1	?	+	+	+	+	+	+	Some concerns
	Wang G_20	Wang G_2016	Somatostatin+	Somatostatin	Organ failure	1	?	+	+	+	+	+	+	Some concerns
	Wang R_20	Wang R_2013	Octreotide	Placebo	Organ failure	1	+	+	+	+	+	+	+	Low risk



# 使用RCT研究進行統合分析→確認研究品質

## ROB graph across studies: example



# 使用Cohort研究進行統合分析→確認研究品質

## Newcastle-Ottawa Quality Assessment Scale: Cohort Studies

### 由兩個人double check

- Selection (4)
  - Most observational studies do not have a protocol:  
Risk of “cherry-picking” outcomes (**reporting bias**)
- Comparability (1)
  - Particular care should be given to **confounding**
- Outcome (3)
  - Focus on the **design “features”** rather than design “labels”  
(**cohort vs. case-control, prospective vs. retrospective**)

# 使用Cohort研究進行統合分析→確認研究品質

## Newcastle-Ottawa Quality Assessment Scale: Cohort Studies

### Selection

1. Representativeness of the exposed cohort
  - a) truly representative of the average \_\_\_\_\_ (describe) in the community ♦
  - b) somewhat representative of the average \_\_\_\_\_ in the community ♦
  - c) selected group of users eg nurses, volunteers
  - d) no description of the derivation of the cohort
  
2. Selection of the non exposed cohort
  - a) drawn from the same community as the exposed cohort ♦
  - b) drawn from a different source
  - c) no description of the derivation of the non exposed cohort
  
3. Ascertainment of exposure to implants
  - a) secure record (eg surgical records) ♦
  - b) structured interview ♦
  - c) written self report
  - d) no description
  
4. Demonstration that outcome of interest was not present at start of study
  - a) yes ♦
  - b) no

# 使用Cohort研究進行統合分析→確認研究品質

## Newcastle-Ottawa Quality Assessment Scale: Cohort Studies

### Comparability

1. Comparability of cohorts on the basis of the design or analysis
  - a) study controls for \_\_\_\_\_ (select the most important factor) ◆
  - b) study controls for any additional factor (This criteria could be modified to indicate specific control for a second important factor.) ◆

# 使用Cohort研究進行統合分析→確認研究品質

## Newcastle-Ottawa Quality Assessment Scale: Cohort Studies

### Outcome

1. Assessment of outcome
  - a) independent blind assessment ♦
  - b) record linkage ♦
  - c) self report
  - d) no description
  
2. Was follow up long enough for outcomes to occur
  - a) yes (select an adequate follow up period for outcome of interest) ♦
  - b) no
  
3. Adequacy of follow up of cohorts
  - a) complete follow up - all subjects accounted for ♦
  - b) subjects lost to follow up unlikely to introduce bias - small number lost - > \_\_\_ % (select an adequate %) follow up, or description of those lost) ♦
  - c) follow up rate < \_\_\_% (select an adequate %) and no description of those lost
  - d) no statement

# 使用RCT研究進行統合分析→確認研究品質





Fig 6 | Meta-analysis plot for overall adverse pregnancy outcome (preterm birth <37 weeks of gestation and spontaneous abortions/stillbirths). M-H=Mantel-Haenszel model

Polyzos et al, BMJ 2010

# 研究出現高異質性怎麼辦？

$I^2 \leq 50\%$ : Homogeneous (fixed effect)  
 $I^2 > 50\%$ : Heterogeneity (random effect mode)



# 研究出現高異質性怎麼辦？

- 不要先急著作統合分析

- 統合性迴歸分析 (meta-regression)

- 次群組分析 (subgroup-analysis)：找出具有明顯的 category 差別的變項

- 總論文數小於10篇以下，盡量不要作統合性迴歸分析 → **Egger' s test**

- 敏感度分析 (sensitivity analysis)：

- 將某些不合適的論文（例如壁報或品質差的論文）刪除



- 使用 **Random effect model**



# 圖像化評估 Publication Bias: Funnel Plot

「出版性偏差」 (publication bias)：研究的質素相若，但報告較大效應值的大型研究，相比於報告較小、或沒有效應的小型研究更常被發表出版的情況。

「出版性偏差」的風險：會令綜合性的研究並不能準確地代表某主題的所有研究，而只偏重於較極端的結果。



漏斗圖：(A) 有出版性偏差、(B) 無出版性偏差


# 圖像化評估 Publication Bias: Funnel Plot

## Introduction to the "metafunnel" Module


```
search(metafunnel)  
search(metabias)
```

insheet using "D:\助理研究員\中榮醫研部-生統小組\全院教育課程規劃-2022oct\111年第4季\20221228-初探Meta-analysis\afreg.csv"

### metafunnel logrr selogrr



### metafunnel logor selogor




# 圖像化評估 Publication Bias: Funnel Plot

樣本數太少?

Small size effect: Egger's test

insheet using "D:\助理研究員\中榮醫研部-生統小組\全院教育課程規劃-2022oct\111年第4季\20221228-初探Meta-analysis\afreg.csv"

metafunnel logor selogor, egger



search(metafunnel)

search(metabias)

metabias logor selogor, egger

```
. metabias logor selogor, egger graph
```

Note: default data input format (theta, se\_theta) assumed.

Tests for Publication Bias

Begg's Test

```
adj. Kendall's Score (P-Q) =      -12
  Std. Dev. of Score =      18.27 (corrected for ties)
  Number of Studies =         14
  z =      -0.66
  Pr > |z| =      0.511
  z =      0.60 (continuity corrected)
  Pr > |z| =      0.547 (continuity corrected)
```

Egger's test

Std_Eff	Coef.	Std. Err.	t	P> t	[95% Conf. Interval]	
slope	.3068297	1.247459	0.25	0.810	-2.41115	3.024809
bias	-2.8082	3.130834	-0.90	0.387	-9.629702	4.013302


# 若有 Publication Bias，則做 Meta-regression 去看是否有差異？

search (metareg)

#單看特定變數會不會影響結局 (只能放一個變數)

AF duration 會不會影響復發

metareg logor af\_duration\_month , wsse(selogor) graph



```
. metareg logor af_duration_month , wsse(selogor) graph
```

Meta-regression	Number of obs	=	12
REML estimate of between-study variance	tau2	=	.02237
% residual variation due to heterogeneity	I-squared_res	=	13.84%
Proportion of between-study variance explained	Adj R-squared	=	-82.67%
<b>with Knapp-Hartung modification</b>			


logor	Coef.	Std. Err.	t	P> t	[95% Conf. Interval]	
af_duratio~h	.0032216	.0072379	0.45	0.666	-.0129054	.0193486
_cons	-.7446471	.2116059	-3.52	0.006	-1.216134	-.2731598

afreg.csv

若Meta-regression有差異 →  
把有差異的那群分層去比較 (Sub-group analysis)

insheet using "D:\助理研究員\中榮醫研部-生統小組\全院教育課程規劃-2022oct\111年第4季\20221228-初探Meta-analysis\nodm.csv"


**#Sub-group analysis**  
(依adjust與否分層): Random-effects model  
metan logrr selogrr, random eform by(sex)




# 總結

- 僅由單一個隨機分派研究的結果來下結論是一種比較危險的行為，萬一這個結果有隨機錯誤時（error by chance），我們就有可能對某個醫學議題造成誤判。
- 統合分析可以提供較客觀的整合分析結果，對於不合適的研究我們也可藉由敏感性分析將其剔除，而使分析結果更正確。
- 隨機分派研究與觀察性研究的證據強度（level of evidence）是不同的，我們在看一篇統合分析的論文時一定要注意所選取論文的研究種類、品質、和訊息強度。

統合分析和隨機分派研究論文結果抵觸的可能原因：  
某些特定族群被過度呈現





# 記得填寫滿意度問卷喔！



## 生統小組：統計方法教育訓練

